In the News

Sunflower Therapeutics Announces SK bioscience’s $2M SAFE Investment

Sunflower Therapeutics, a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has participated in Sunflower’s simple agreement for future equity (SAFE), a flexible agreement providing future equity rights without immediate valuation, with a $2M subscription to solidify their support for the companies’ ongoing research and development R&D collaborations.

read more

Sunflower Therapeutics Awarded $9+M

Grants from the Bill & Melinda Gates Foundation support the optimization of the Dahlia™ small-footprint protein manufacturing system and the de-risking of several protein candidates using Sunflower’s proprietary manufacturing approach.

read more